Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 33, Issue 1, Pages 225-237
Publisher
American Society of Nephrology (ASN)
Online
2021-11-04
DOI
10.1681/asn.2021070942
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial
- (2019) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
- (2019) Rajiv Agarwal et al. LANCET
- Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom
- (2019) Cecilia Linde et al. Journal of the American Heart Association
- Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
- (2018) Csaba P Kovesdy et al. EUROPEAN HEART JOURNAL
- Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
- (2018) Akshay S. Desai et al. JOURNAL OF CARDIAC FAILURE
- Renal mineralocorticoid receptor and electrolyte homeostasis
- (2015) Andrew S. Terker et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist
- (2014) Orly Vardeny et al. Circulation-Heart Failure
- Management of hyperkalaemia in chronic kidney disease
- (2014) Csaba P. Kovesdy Nature Reviews Nephrology
- Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
- (2014) Ivana Lazich et al. SEMINARS IN NEPHROLOGY
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started